<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-26 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-26</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-26</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <p><strong>Paper ID:</strong> paper-fcc794d59b6567b127253557b5b02bda2e201484</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/fcc794d59b6567b127253557b5b02bda2e201484" target="_blank">Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing</a></p>
                <p><strong>Paper Venue:</strong> Cell</p>
                <p><strong>Paper TL;DR:</strong> Exome and genome sequences and whole-genome sequence analysis revealed frequent structural rearrangements, including in-frame exonic alterations within EGFR and SIK2 kinases, which are attractive targets for biological characterization and therapeutic targeting of lung adenocarcinoma.</p>
                <p><strong>Cost:</strong> 0.026</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e26.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e26.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR (general)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A receptor tyrosine kinase frequently activated by point mutations, in-frame deletions, and copy-number gain in lung adenocarcinoma; a clinically actionable RTK driver.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR activating point mutations (e.g., classical hotspots) and copy-number gain</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation; amplification</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK → RTK/RAS/RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>17% mutated (point mutations); 22% copy-number gain (as reported in cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (WES/WGS, SNP array) and statistical analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Significantly enriched in never-/light smokers and mutation spectrum cluster 1; anticorrelated with KRAS</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Known sensitivity to EGFR tyrosine kinase inhibitors (general literature); targeted therapy relevance noted in paper</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing, whole-genome sequencing, SNP array (copy number)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e26.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR exon25-26 deletion</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR C-terminal deletion removing exons 25 and 26 (EGFR Ex25&26 del)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A novel in-frame C-terminal deletion of EGFR identified by WGS in a lung adenocarcinoma, analogous to EGFR C-terminal deletions previously reported in glioblastoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR exon 25-26 in-frame deletion (C-terminal deletion)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>in-frame deletion (structural rearrangement)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK → RTK/RAS/RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Observed in 1 WGS case (frequency in cohort: 1/24 WGS cases; overall 1/183 total cases)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>whole-genome sequencing (structural variant discovery), validation by PCR, functional cell-based assays</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td>Ectopic expression in NIH 3T3 induced soft-agar colony formation and constitutive EGFR/AKT phosphorylation; Ba/F3 transformation sensitive to erlotinib</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Co-occurred with a second EGFR p.G719S mutation in the same tumor (suggests possible co-operativity/subclonality); found in WGS-profiled tumor</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Shown experimentally to be sensitive to EGFR TKI erlotinib in Ba/F3 cells in this study</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183 (24 WGS-assayed cases for rearrangements)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-genome sequencing (paired-end and split-read mapping), PCR validation; functional assays in NIH 3T3 and Ba/F3 cell lines</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e26.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR p.G719S</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>EGFR glycine 719 to serine substitution (p.G719S)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An EGFR kinase-domain point mutation observed in this cohort; known activating substitution in EGFR kinase.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>EGFR p.G719S</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>EGFR / RTK → RTK/RAS/RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Observed in at least one tumor in cohort (exact cohort frequency not enumerated separately)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (WGS) - observed in tumor with EGFR C-terminal deletion</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Co-occurred with EGFR exon25-26 deletion in same tumor (noted in paper)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Classically considered an activating EGFR mutation with implications for EGFR-targeted therapy (literature); no direct clinical response data in this paper</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-genome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e26.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KRAS proto-oncogene GTPase</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A small GTPase commonly activated by hotspot point mutations in lung adenocarcinoma leading to constitutive RAS pathway signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KRAS activating point mutations (hotspot codons)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KRAS → RAS/RAF/MAPK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>27% mutated (cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (WES/WGS) and statistical selection</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>KRAS driver alterations significantly associated with mutation spectrum cluster 3; anticorrelated with EGFR; often found in smokers</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing, whole-genome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e26.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF proto-oncogene serine/threonine kinase</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A serine/threonine kinase in the RAF family that is recurrently mutated in lung adenocarcinoma at lower frequency than KRAS/EGFR.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>BRAF activating point mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>BRAF → RAS/RAF/MAPK pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>8% mutated (cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (WES/WGS), statistical analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>BRAF is a known therapeutic target in other cancers; paper does not present direct treatment data</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e26.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ALK fusions</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Anaplastic lymphoma kinase gene fusions (e.g., EML4-ALK and others)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Recurrent oncogenic gene fusions reported in lung adenocarcinoma that activate ALK kinase and are targetable by ALK inhibitors; discussed as previously reported.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ALK gene fusions (e.g., EML4-ALK)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion (in-frame translocation)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ALK / RTK → RTK/RAS/RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Mentioned as ~2-7% (literature cited in paper)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature mention (prior clinical sequencing studies); not detected in this WGS sample set</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Known clinically to occur in subsets of patients, often never-smokers (literature); not directly evaluated in cohort</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Clinically targetable with ALK inhibitors (literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183 (no ALK in WGS set reported)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Not detected in this study's WGS cases; mentioned from prior studies</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e26.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RET fusions</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>RET proto-oncogene gene fusions (e.g., KIF5B-RET)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Literature-reported in-frame gene fusions activating RET kinase in a subset of lung adenocarcinomas; mentioned in paper background.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>RET gene fusions (e.g., KIF5B-RET)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene fusion (in-frame translocation)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>RET / RTK → RTK/RAS/RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Mentioned as reported in prior studies (frequency not enumerated in this paper)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature mention; prior whole-genome/transcriptome studies</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>RET fusions are being pursued as therapeutic targets in trials (paper notes ongoing clinical pursuit)</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183 (background mention)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Not newly detected here (mentioned from prior studies)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e26.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ROS1 rearrangements</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ROS1 receptor tyrosine kinase rearrangements (e.g., ROS1 fusions)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Recurrent ROS1 gene fusions reported in lung adenocarcinoma; in this study one out-of-frame ROS1-CD74 translocation was observed without the reciprocal active event.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ROS1-CD74 translocation (out-of-frame observed in one patient)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>gene translocation (out-of-frame in this cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ROS1 / RTK → RTK/RAS/RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Prior reports indicate 2-7% (paper cites literature); this cohort observed one out-of-frame ROS1-CD74 in a single patient (not the canonical active fusion)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>whole-genome sequencing detection (single case) and literature mention</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Canonical ROS1 fusions are targetable (literature), but the out-of-frame event observed here is not the known activating reciprocal fusion</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183 (24 WGS cases)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-genome sequencing (WGS)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e26.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ERBB2 (HER2)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ERBB2 (also called HER2/neu) receptor tyrosine kinase</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A member of the ERBB family that can be activated by point mutation or amplification in lung adenocarcinoma; mentioned as a known mutated oncogene.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ERBB2 activating mutations and/or amplification</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation; amplification</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ERBB2 / RTK → RTK/RAS/RAF pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Reported in literature and mentioned in paper (not significant in this cohort's statistical analysis); specific cohort frequency not provided</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>literature mention and presence in curated gene list; some canonical events observed but not significant by InVEx</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>ERBB2 alterations are being pursued therapeutically, but no direct data in this paper</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing (some events observed but not statistically enriched)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e26.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PIK3CA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A PI3K catalytic subunit gene mutated in multiple cancers including lung adenocarcinoma; included in CGC analyses in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>PIK3CA point mutations and/or amplifications</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation; copy-number alteration</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>PIK3CA → PI3K/AKT pathway (downstream of RTKs)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Mentioned as recurrently altered in lung adenocarcinoma (literature); paper included it in CGC analysis but cohort frequency not explicitly enumerated</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling and CGC-focused InVEx analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e26.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NF1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neurofibromin 1 (tumor suppressor)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A negative regulator of RAS signaling that is recurrently inactivated in lung adenocarcinoma, contributing to pathway activation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>NF1 loss-of-function mutations/deletions</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>loss-of-function mutation; deletion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>NF1 → RAS regulation (RAS/RAF pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>11% mutated (cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (WES/WGS) and statistical analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>NF1 mutations were significantly depleted in mutation spectrum cluster 1 and co-occurred with U2AF1 mutations</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e26.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TP53</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Tumor protein p53</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A canonical tumor suppressor frequently mutated in lung adenocarcinoma, associated with worse progression-free survival in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>TP53 truncating and missense mutations; copy-number loss</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense/truncating); deletion (copy-number loss)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>TP53 tumor suppressor pathway</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>50% mutated (cohort); 18% copy-number loss reported</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (WES/WGS, SNP array)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>TP53 mutations associated with significantly reduced progression-free survival (p = 0.0014)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing; copy-number from SNP array</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.12">
                <h3 class="extraction-instance">Extracted Data Instance 12 (e26.12)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>STK11 (LKB1)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Serine/threonine kinase 11 (LKB1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A tumor suppressor kinase frequently inactivated in lung adenocarcinoma, often by mutation or deletion.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>STK11 loss-of-function mutations and deletions</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense/truncating); deletion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>STK11 tumor suppressor pathway (affects AMPK-related kinases)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>15% mutated (cohort); examples of rearrangement deleting translational start site noted in WGS</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (WES/WGS), rearrangement analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>STK11 driver alterations significantly enriched in mutation spectrum cluster 2</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183 (24 WGS for rearrangements)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing, whole-genome sequencing (for structural events)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.13">
                <h3 class="extraction-instance">Extracted Data Instance 13 (e26.13)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CDKN2A</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cyclin-dependent kinase inhibitor 2A (p16INK4A/p14ARF)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A tumor suppressor frequently inactivated in lung adenocarcinoma by homozygous deletion, mutation, or structural rearrangement.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>CDKN2A homozygous deletion and structural rearrangements</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>copy-number loss (homozygous deletion); gene rearrangement (fusion, deletion)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>CDKN2A → cell cycle regulation (RB pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>24% losses (10% homozygous) in cohort; high rearrangement rate (4.3 rearrangements per sequenced Mb for its size)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>SNP array copy-number analysis and WGS rearrangement mapping</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183 (24 WGS for rearrangements)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>SNP array (copy number), whole-genome sequencing (rearrangements)</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.14">
                <h3 class="extraction-instance">Extracted Data Instance 14 (e26.14)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SMARCA4</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 4</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A chromatin remodeling ATPase and tumor suppressor recurrently mutated in lung adenocarcinoma; part of epigenetic regulation alterations found in cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>SMARCA4 truncating and missense mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense/truncating)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>Chromatin remodeling / epigenetic regulation</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Reported among significantly mutated genes (frequency consistent with prior reports; exact percent not restated in main text here)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (WES/WGS) and statistical selection</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.15">
                <h3 class="extraction-instance">Extracted Data Instance 15 (e26.15)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KEAP1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Kelch-like ECH-associated protein 1</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Negative regulator of NRF2 antioxidant response pathway, recurrently inactivated in lung adenocarcinoma via mutation or deletion.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>KEAP1 loss-of-function mutations and deletions</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense/truncating); copy-number loss</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>KEAP1/NRF2 oxidative stress regulation</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>12% mutated (cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (WES/WGS)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>KEAP1 mutations anticorrelated with mutation spectrum cluster 1 (never/light smokers)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.16">
                <h3 class="extraction-instance">Extracted Data Instance 16 (e26.16)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SMAD4</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SMAD family member 4</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A tumor suppressor in TGF-β signaling with recurrent mutations in a minority of lung adenocarcinomas.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>SMAD4 mutations and copy-number loss</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation; deletion</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>TGF-β signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>3% mutated (cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (WES/WGS)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.17">
                <h3 class="extraction-instance">Extracted Data Instance 17 (e26.17)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CTNNB1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Catenin beta 1 (β-catenin)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A WNT pathway effector occasionally mutated in lung adenocarcinoma; identified in CGC-focused analyses in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>CTNNB1 activating mutations</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>WNT/β-catenin signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Detected in CGC analysis (specific cohort frequency not stated in main text)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>CGC-focused InVEx analysis of WES data</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.18">
                <h3 class="extraction-instance">Extracted Data Instance 18 (e26.18)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ARID1A</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>AT-rich interaction domain-containing protein 1A (BAF250A)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A SWI/SNF chromatin remodeling complex member recurrently truncated or frameshifted in this cohort (8% of cases), implicating epigenetic deregulation in LUAD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>ARID1A truncating substitutions and frameshift indels (loss-of-function)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>loss-of-function mutation (nonsense, frameshift)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>Chromatin remodeling / SWI-SNF complex</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>8% of cases (cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>whole-exome sequencing and LOF InVEx statistical enrichment</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing; statistical LOF enrichment analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.19">
                <h3 class="extraction-instance">Extracted Data Instance 19 (e26.19)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>RBM10</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>RNA binding motif protein 10</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An RNA-binding protein recurrently inactivated in lung adenocarcinoma by nonsense, frameshift, or splice-site mutations (observed in ~7% of cases), suggesting involvement of splicing regulation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>RBM10 truncating mutations (nonsense, frameshift, splice-site)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>loss-of-function mutation (truncating and splice-site)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>RNA splicing / RNA-binding</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>12/183 cases (~7%) mutated; 7/12 mutated cases had nonsense/frameshift/splice-site events (4% of overall cohort had truncating events)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>genomic profiling (WES) with statistical enrichment (PPH2 InVEx)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>RBM10 mutations co-occurred with mutations in KRAS, EGFR, and PIK3CA</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing; statistical analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.20">
                <h3 class="extraction-instance">Extracted Data Instance 20 (e26.20)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>U2AF1</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>U2 small nuclear RNA auxiliary factor 1</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A splicing factor found recurrently mutated at a hotspot (c.101C>T, p.S34F) in ~3% of cases in this study; reported here as the first identification in an epithelial tumor.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>U2AF1 p.S34F recurrent missense mutation</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>point mutation (missense hotspot)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>Spliceosome / RNA splicing</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>3% of cases (5/183; four of five had identical p.S34F)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>whole-exome sequencing, statistical enrichment (PPH2 InVEx)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>U2AF1 mutations associated with significantly reduced progression-free survival; one U2AF1 p.S34F occurred with activating KRAS (p.Q61H), suggesting independence from canonical proliferation drivers in some cases</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-exome sequencing; statistical InVEx analysis</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.21">
                <h3 class="extraction-instance">Extracted Data Instance 21 (e26.21)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SIK2 duplication</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Salt-inducible kinase 2 in-frame kinase domain duplication</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An in-frame duplication affecting the SIK2 kinase domain detected by WGS in a tumor lacking canonical oncogene mutations; potentially activating given proximity to regulatory Thr-175.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>In-frame kinase domain duplication in SIK2</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>in-frame duplication (structural rearrangement)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>SIK2 (AMPK-related kinase family) / kinase signaling</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Observed in WGS set (1 or small number of WGS cases); exact cohort frequency not stated</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>whole-genome sequencing (structural variant detection) and qPCR validation</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Found in a tumor without mutations in canonical lung adenocarcinoma oncogenes (noted by authors)</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Potentially targetable kinase alteration but no functional/therapeutic data provided</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183 (24 WGS cases surveyed for rearrangements)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-genome sequencing, qPCR validation</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.22">
                <h3 class="extraction-instance">Extracted Data Instance 22 (e26.22)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ROCK1 duplication</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Rho-associated coiled-coil containing protein kinase 1 exon duplication</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A large in-frame exon duplication (19 exons) in ROCK1 detected by WGS in the cohort, potentially altering kinase function and occurring in a tumor lacking canonical oncogene mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>19-exon in-frame duplication in ROCK1</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>in-frame duplication (structural rearrangement)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>ROCK1 / Rho signaling (serine/threonine kinase)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>Observed in WGS set (1 WGS case); exact cohort frequency not stated</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>whole-genome sequencing (structural variant detection)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td>Detected in a tumor without mutations in canonical lung oncogenes</td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td>Potential kinase target but no functional data provided in paper</td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183 (24 WGS cases examined for rearrangements)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-genome sequencing</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.23">
                <h3 class="extraction-instance">Extracted Data Instance 23 (e26.23)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CDKN2A rearrangements</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CDKN2A structural rearrangements (gene fusions/deletions)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Structural rearrangements targeting CDKN2A were frequent relative to its size and included out-of-frame antisense fusions and in-frame deletions, representing an additional mechanism of inactivation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>CDKN2A rearrangements (antisense fusions, in-frame deletions)</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>structural rearrangement (genic fusions/deletions)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>CDKN2A → cell cycle regulation</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>High rearrangement rate reported (4.3 rearrangements per sequenced Mb for CDKN2A); multiple cases with rearrangements described (at least 3 specific cases mentioned)</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>whole-genome sequencing rearrangement mapping and PCR validation</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183 (24 WGS cases)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Whole-genome sequencing; PCR validation</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.24">
                <h3 class="extraction-instance">Extracted Data Instance 24 (e26.24)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NKX2-1 amplification</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NK2 homeobox 1 (TTF-1) focal amplification</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Lineage-specific transcription factor that is focally amplified in a subset of lung adenocarcinomas and previously reported as oncogene in LUAD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>NKX2-1 focal amplification</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>copy-number gain (focal amplification)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>Lineage survival oncogene / transcription factor</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>18% gains (10% focal) in cohort</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>SNP array copy-number analysis (literature-validated locus)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>SNP array copy-number profiling</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.25">
                <h3 class="extraction-instance">Extracted Data Instance 25 (e26.25)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TERT gain</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>TERT copy-number gain (telomerase reverse transcriptase)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Frequent copy-number gains of TERT observed in cohort, possibly contributing to replicative immortality.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>TERT gains and focal amplifications</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>copy-number gain (amplification)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>TERT / telomerase activity</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>42% gains overall (15% focal) in cohort</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>SNP array copy-number analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>SNP array</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e26.26">
                <h3 class="extraction-instance">Extracted Data Instance 26 (e26.26)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of driver alterations, oncogenic mutations, or genomic changes in lung adenocarcinoma, including both known drivers in RTK/RAS/RAF pathway and novel/rare drivers, especially those found in tumors lacking canonical driver mutations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>MYC gain</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>MYC (proto-oncogene) copy-number gain</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Copy-number gains of MYC observed in a substantial fraction of the cohort, a canonical oncogenic amplification.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>driver_alteration</strong></td>
                            <td>MYC copy-number gain/amplification</td>
                        </tr>
                        <tr>
                            <td><strong>alteration_type</strong></td>
                            <td>copy-number gain (amplification)</td>
                        </tr>
                        <tr>
                            <td><strong>gene_or_pathway</strong></td>
                            <td>MYC transcriptional regulator (proliferative signaling)</td>
                        </tr>
                        <tr>
                            <td><strong>is_rtk_ras_raf_pathway</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_luad</strong></td>
                            <td>31% gains in cohort</td>
                        </tr>
                        <tr>
                            <td><strong>frequency_in_driver_negative</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_type</strong></td>
                            <td>SNP array copy-number analysis</td>
                        </tr>
                        <tr>
                            <td><strong>functional_evidence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_associations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>therapeutic_implications</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_cohort_size</strong></td>
                            <td>183</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>SNP array copy-number profiling</td>
                        </tr>
                        <tr>
                            <td><strong>novel_or_rare</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing', 'publication_date_yy_mm': '2012-09'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Somatic mutations affect key pathways in lung adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Diverse somatic mutation patterns and pathway alterations in human cancers <em>(Rating: 1)</em></li>
                <li>A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing <em>(Rating: 2)</em></li>
                <li>Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer <em>(Rating: 1)</em></li>
                <li>Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>